Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

284 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Prognostic value of the neutrophil/lymphocyte ratio in enteropancreatic neuroendocrine tumors.
Grenader T, Pavel ME, Ruszniewski PB, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Truong Thanh XM, Caplin ME; CLARINET Study Group. Grenader T, et al. Among authors: cadiot g. Anticancer Drugs. 2020 Mar;31(3):216-222. doi: 10.1097/CAD.0000000000000909. Anticancer Drugs. 2020. PMID: 31977567 Free PMC article. Clinical Trial.
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Blumberg J, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. Among authors: cadiot g. N Engl J Med. 2014 Jul 17;371(3):224-33. doi: 10.1056/NEJMoa1316158. N Engl J Med. 2014. PMID: 25014687 Free article. Clinical Trial.
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: the CLARINET open-label extension study.
Caplin ME, Pavel M, Ćwikła JB, Phan AT, Raderer M, Sedláčková E, Cadiot G, Wolin EM, Capdevila J, Wall L, Rindi G, Langley A, Martinez S, Gomez-Panzani E, Ruszniewski P; CLARINET Investigators. Caplin ME, et al. Among authors: cadiot g. Endocr Relat Cancer. 2016 Mar;23(3):191-9. doi: 10.1530/ERC-15-0490. Epub 2016 Jan 7. Endocr Relat Cancer. 2016. PMID: 26743120 Free PMC article. Clinical Trial.
Treatment outcomes of advanced digestive well-differentiated grade 3 NETs.
de Mestier L, Lamarca A, Hernando J, Zandee W, Alonso-Gordoa T, Perrier M, Walenkamp AM, Chakrabarty B, Landolfi S, Van Velthuysen MF, Kats-Ugurlu G, Caminoa A, Ronot M, Manoharan P, Garcia-Alvarez A, Brabander T, García Gómez-Muriel MI, Cadiot G, Couvelard A, Capdevila J, Pavel ME, Cros J. de Mestier L, et al. Among authors: cadiot g. Endocr Relat Cancer. 2021 Jun 23;28(8):549-561. doi: 10.1530/ERC-21-0109. Endocr Relat Cancer. 2021. PMID: 34061764
Alkylating agent rechallenge in metastatic pancreatic neuroendocrine tumors.
De Rycke O, Walter T, Perrier M, Hentic O, Lombard-Bohas C, Coriat R, Cadiot G, Couvelard A, Ruszniewski P, Cros J, de Mestier L. De Rycke O, et al. Among authors: cadiot g. Endocr Relat Cancer. 2021 Jun 11;28(7):457-466. doi: 10.1530/ERC-21-0034. Endocr Relat Cancer. 2021. PMID: 33979778
Ki67 proliferation index, hepatic tumor load, and pretreatment tumor growth predict the antitumoral efficacy of lanreotide in patients with malignant digestive neuroendocrine tumors.
Palazzo M, Lombard-Bohas C, Cadiot G, Matysiak-Budnik T, Rebours V, Vullierme MP, Couvelard A, Hentic O, Ruszniewski P. Palazzo M, et al. Among authors: cadiot g. Eur J Gastroenterol Hepatol. 2013 Feb;25(2):232-8. doi: 10.1097/MEG.0b013e328359d1a6. Eur J Gastroenterol Hepatol. 2013. PMID: 23108416
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial)--a phase II non-randomised trial.
Mitry E, Walter T, Baudin E, Kurtz JE, Ruszniewski P, Dominguez-Tinajero S, Bengrine-Lefevre L, Cadiot G, Dromain C, Farace F, Rougier P, Ducreux M. Mitry E, et al. Among authors: cadiot g. Eur J Cancer. 2014 Dec;50(18):3107-15. doi: 10.1016/j.ejca.2014.10.001. Epub 2014 Oct 18. Eur J Cancer. 2014. PMID: 25454413 Clinical Trial.
284 results